AOTI

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, AOTI sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 1 completed later-stage tilt upper quartile by trial count

AOTI: 3 sponsored US clinical trials, 1 recruiting.

AOTI sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Leg Ulcer (VLU), with 1 trials.

Upper-quartile sponsor footprint

AOTI sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING Phase 4

Trial to Evaluate Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic Venous Leg Ulcers

NCT06754735
COMPLETED NA

Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers

NCT02326337
TERMINATED NA

Evaluation of Topical Wound Oxygen (two2) Therapy

NCT00871312

Phase Distribution

PhaseTrial count
Phase 4 1

Therapeutic Areas

Venous Leg Ulcer (VLU) 1

Where AOTI enrollment is open (later-stage tilt)

1 recruiting of 3 indexed (33% open); 1 completed (33%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Venous Leg Ulcer (VLU) (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

AOTI: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

AOTI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share AOTI10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
AOTI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

AOTI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this AOTI page

3 registered trials is a research-attention snapshot, not an endorsement of AOTI or any single study.

  • 1 of AOTI's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Venous Leg Ulcer (VLU) is the condition AOTI studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Leg Ulcer (VLU) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

AOTI pipeline card: 3 registered trials from official public datasets.Report a data error.